Pharmaceutical Media Intelligence
Built for Pharma Comms, Regulatory, and Medical Affairs
Pharma communications teams spend too much time chasing stories their platform flagged too late, or missed entirely. Fullintel delivers analyst-reviewed intelligence across paywalled sources, global regulators, and 90+ languages, configured for your therapeutic areas and in your inbox before your morning standup.
The OPDP letter your platform missed is already in your competitor's morning briefing.
Automated monitoring does not reach Pink Sheet, STAT, Endpoints, Scrip, or the regulatory and trade sources that pharma communications, regulatory, and medical affairs teams rely on. Fullintel does. A pharma analyst reviews every briefing before it lands in your inbox.
- Paywalled and subscription sources that automated tools cannot access.
- Analyst review on every briefing, not raw keyword alerts.
- FDA, EMA, Health Canada, and MHRA are monitored in real time.
- 24/7 crisis escalation with context, not just a mention count.
Book Your Pharma Intelligence Demo
20 minutes. Scoped to your therapeutic areas, your regulatory exposure, and the sources your current setup is missing.
Scoped to your priorities, not a canned platform walkthrough.
You will speak with a pharma media intelligence specialist who has worked with nearly half of the Top 100 global pharmaceutical communications teams.
Pharmaceutical Media Intelligence
The OPDP letter your platform missed is already in your competitor's morning briefing.
Automated monitoring does not reach Pink Sheet, STAT, Endpoints, Scrip, or the regulatory and trade sources that pharma communications, regulatory, and medical affairs teams rely on. Fullintel does. A pharma analyst reviews every briefing before it lands in your inbox.
- Paywalled and subscription sources that automated tools cannot access.
- Analyst review on every briefing, not raw keyword alerts.
- FDA, EMA, Health Canada, and MHRA are monitored in real time.
- 24/7 crisis escalation with context, not just a mention count.
Book Your Pharma Intelligence Demo
20 minutes. Scoped to your therapeutic areas, your regulatory exposure, and the sources your current setup is missing.
Scoped to your priorities, not a canned platform walkthrough.
You will speak with a pharma media intelligence specialist who has worked with nearly half of the Top 100 global pharmaceutical communications teams.
Experience Our Award Winning Solutions
AMEC
Gold Award Winner
IPRRC
Arthur W. Page Center Award Winner
Strategic Media Analysis
Best Solution Provider
AI-Automation Resource
Best Solution Provider
Our Customers
Working with some of the world's most trusted brands
50%
Average cost reduction
300,000+
Global sources monitored
24/7
Analyst coverage
Top 100
Global pharmaceutical companies served
How the Intelligence Reaches Your Team
What you get from Fullintel pharma
Pharma communications teams buy three things from Fullintel: a daily news brief curated for their portfolio, scheduled and ad hoc analysis for leadership, and 24/7 crisis monitoring with real-time escalation. Each runs on the same MATT AI engine, trained on a decade of real-world, high-quality pharmaceutical data.
Executive News Briefings
Daily expert-curated news summaries delivered before your morning standup. Configured by therapeutic area, geography, competitor, and stakeholder group. Behind-the-paywall sources can help manage your subscription costs.
Strategic Media Analysis
In-depth analysis reports for leadership and board audiences. Cross-region consolidation, KPI standardization, and KOL and HCP sentiment work. Built for the people who brief the C-suite, not the people who maintain the dashboard.
24/7 Situation Management
Around-the-clock crisis and issues monitoring with analyst escalation. When adverse event coverage breaks or litigation mentions surface overnight, your designated contacts receive context, not a dashboard ping.
What Fullintel covers
Built for the Complexity of Pharmaceutical Communications
Regulatory bodies. Trade press behind paywalls. HCP forums. Patient advocacy communities.
Competitor pipelines. Fullintel monitors them and delivers only what your team needs to act on.
FDA, EMA, Health Canada, and global regulatory monitoring
Real-time alerts on approvals, recalls, OPDP enforcement
letters, Complete Response Letters, and safety communications across the FDA, EMA, Health Canada, MHRA, PMDA, and other jurisdictions. Your regulatory affairs team sees the alert before it becomes the story.
Adverse event handling and crisis escalation
Every Fullintel analyst on a pharma account is trained in adverse event recognition and in handling pharmacovigilance. When AE coverage surfaces, your team receives an escalation with analyst context attached, routed to the right contact per the protocol we configure with you during onboarding. This is the part that automated tools cannot do and will never be able to do; we have the vertical expertise to be your trusted partner.
Clinical trial, pipeline, and HCP coverage
Track Phase II, Phase III, and commercial product coverage across news, HCP forums, patient communities, and investor press. Configurable by therapeutic area, indication, and geographic market. The same configuration drives your briefings, your analysis, and your escalation rules.
Competitor R&D and investor intelligence
Monitor competitor pipeline milestones, payer decisions, formulary coverage, and pricing announcements. Your commercial and strategy teams see what is moving markets before earnings calls run.
HCP, KOL, and patient sentiment
Understand how key opinion leaders, healthcare professionals, and patient advocacy communities discuss your products. Critical input for medical affairs, commercial, and regulatory teams managing label perception and educational programs.
Multi-region, multi-language coverage
Fullintel monitors in 90-plus languages across every major pharma geography. Essential for global brands navigating parallel regulatory timelines and divergent media environments. One framework. Consistent KPIs. No regional vendor stitching.
How Pharma Comms Teams Are Upgrading
The old way and the Fullintel way
| Feature | Legacy Platforms | Fullintel Experience |
|---|---|---|
| Brief Production | ✕ Automated keyword dumps requiring manual cleanup. | ✓ Expert-curated executive summaries by 6 AM. |
| Regional Consolidation | ✕ Multiple vendors with disparate reporting standards. | ✓ Unified global framework with local nuance. |
| Crisis Response | ✕ Lagging alerts that miss midnight social spikes. | ✓ 24/7 human-verified alerts within 15 minutes. |
Source Coverage
The publications that matter most to pharma are the ones that most platforms cannot reach
Pink Sheet. STAT News. Endpoints News. Scrip. The trade publications your regulatory, medical affairs, and communications teams depend on are subscription-only, which means they are invisible to automated monitoring tools built on open-web aggregation.
Fullintel covers them through licensed content partnerships and analyst-sourced monitoring. When the Pink Sheet runs an OPDP enforcement piece affecting your drug class, or STAT publishes a paywalled analysis of your competitor's FDA filing, it appears in your briefing. Annotated. Verified. Ready to forward.
Source Coverage List
- Pink Sheet. FDA regulatory intelligence and policy analysis.
- STAT News. Pharma and biotech investigative reporting.
- Endpoints News. Biopharma pipeline and clinical trial coverage.
- Scrip. Global pharmaceutical industry intelligence.
- Fierce Pharma. Commercial launch and competitive coverage.
- Reuters Health, AP, and wire services behind aggregator walls.
- Regional pharma trade press in 90-plus languages and markets.
Original vs Syndicated vs Paywalled
Fullintel separates original reporting from syndicated repostings and tags every story by source type. That distinction is the difference between a story breaking and a story being recycled. Most platforms blur it. Yours should not.
Analyst sourced. Verified before delivery.
Your morning pharma brief. Sources included.
See exactly what your current platform is missing
Book a 20-minute call. We will run a coverage audit of your current setup and identify the gaps.
Therapeutic-area specific. No platform tour.
How it works
AI surfaces it. Analysts verify it. Your team acts on it before the story hardens.
The window between a paywalled mention and mainstream coverage is where pharma communications teams either get ahead of a story or spend the week reacting to one. Fullintel was designed for that window.
Source ingestion at platform scale
MATT AI applies the intelligence layer
Pharma analyst review and context
Role-based briefing delivery
Escalation before you search for it
Analyst-reviewed. Four items. Three paywalled sources.
Executive Pharma Brief
Risk watch
OPDP enforcement letter issued to a competitor for a DTC social campaign. Messaging closely mirrors your current campaign creative. Recommend legal and brand team alignment today. The Pink Sheet (paywalled). Analyst note attached.
Analyst insight
Phase III competitor data published under embargo. Coverage is broadly positive. Investor sentiment is shifting in the pre-market. Strategic context in the linked memo. STAT News (paywalled) and Reuters Health (open, original).
Pipeline monitor
Competitor received FDA Breakthrough Therapy designation for a target indication that overlaps with your Phase II program. Endpoints News (paywalled).
Regulatory update
EMA advisory committee published revised guidance on clinical trial disclosure affecting your EU market filings. Scrip (paywalled) and EMA.europa.eu (primary source).
| |||||
| Executive Narrative Novo Nordisk captured a significant global demographic victory with the regulatory expansion of Wegovy to adolescents in India. However, the organization faces macro headwinds at home, as dynamic U.S. price adjustments have prompted domestic financial watchdogs to recalibrate Denmark’s baseline export metrics. Simultaneously, regional compliance critiques regarding municipal research structures require careful management amidst aggressive clinical pipeline progressions and expanded market access frameworks from Eli Lilly. Core Brand Coverage
Industry Landscape The broader metabolic and oncology market remains exceptionally dynamic, marked by aggressive systemic coverage expansions and pivotal data drops across therapeutic verticals.
| |||||
| Confidential - For Internal Use Only © 2026 Novo Nordisk A/S. All Rights Reserved. |
Client Case Study
One of the largest pharmaceutical companies in the world. 47 therapeutic areas. One analyst-curated framework that cut costs by 50 percent.
A leading global pharmaceutical company managed media intelligence across multiple therapeutic lines through fragmented vendors with no consistent methodology. Fullintel consolidated everything (regulatory monitoring, executive briefings, and competitive analysis) into a single analyst-validated framework. Coverage improved. The problem with the 5 a.m. briefing went away. Costs dropped by half.
- 50% reduction in total media intelligence spend.
- 90-plus languages monitored across global markets.
- 3 vendor relationships consolidated into 1.
What they stopped doing
Running 45-minute morning standup calls to review the previous day’s coverage. Chasing paywalled stories, their platform flagged late or missed entirely.
Experience
What Our Clients Are Saying:
Trusted Insights, Proven Results
“Fullintel provided us the intelligence we required, far more cost-effectively than what we had before. Their analyst team worked around the clock to make sure every report met our expectations.”
Communications Director,
Shionogi
"I need to know immediately when clinical trial results are being misinterpreted in the media. Fullintel has caught potentially damaging coverage multiple times before it reached mainstream press, giving us time to respond."
VP, Communications
Global Pharmaceutical Company
"We stopped getting everything and started getting what actually mattered. The coverage gaps we found in our previous platform, especially in trade publications, were significant."
Corporate Affairs Director,
Fortune 500 Life Sciences
Company
Pharma Research Excellence
Angela Dwyer
VP, Insights, Fullintel
Angela leads Fullintel's pharma intelligence research practice. Her original measurement research on pharmaceutical communications, including trust factors in HCP messaging and AI citation rates in earned media, has been presented at PRSA ICON and IPR conferences and published for the IPR Measurement Commission. She has worked directly with Shionogi, Johnson & Johnson, and major global pharma communications teams on cross-region measurement frameworks. AMEC Data and Media Measurement Game-Changer. PRNEWS Top Women in Industry, Champions category. APR-accredited. IPRRC Board member.
- Two-Time PRSA Silver Anvil winner
- AMEC Executive of the Year, 2025
- AMEC Gold Award, Best Multi-Market Reporting
- IPR Measurement Commission Director
- IPRRC Board member
Learn more about Angela Dwyer’s expertise, industry recognition, and thought leadership.
Common Questions
What pharma communications teams ask first
Yes. Fullintel covers paywalled, subscription, and niche trade publications that automated monitoring platforms cannot reach, including Pink Sheet, STAT News, Endpoints, Scrip, and other industry-specific sources. Our analysts use licensed content partnerships and manual sourcing to ensure your briefings include coverage competitors miss entirely.
Yes. We monitor every major regulatory body in real time, including the FDA, EMA, Health Canada, MHRA, and PMDA. Your regulatory and compliance teams receive alerts on approvals, recalls, safety communications, OPDP enforcement letters, and policy developments as they publish, not after they have circulated in the trade press.
Fullintel operates 24/7 with a global analyst team. When adverse event coverage or crisis-level mentions break overnight or on weekends, your designated contacts receive escalation alerts with analyst context, not a dashboard notification you find Monday morning. Routing protocols are configured with your team during onboarding.
Yes. Fullintel tailors monitoring and briefing formats by team, role, product, and therapeutic area. Each team receives a briefing tailored to what they need to act on, at the frequency and format that works for them.
AI is a powerful enrichment layer. It is not a complete source of access. AI cannot reach paywalled regulatory and trade publications, cannot make pharmacovigilance judgments, and cannot replace the human review pharma teams require for adverse event handling. Fullintel runs MATT AI as the intelligence layer that surfaces, clusters, and enriches. Trained pharma analysts validate the output before it reaches your team. That combination is the product.
Automated platforms miss paywalled sources, miss niche trade publications, and require significant internal cleanup to remove irrelevant content. Fullintel clients typically consolidate two or three vendor relationships into one, reduce morning brief production time materially, and eliminate the analyst time spent chasing stories their platform flagged too late or missed entirely. Most clients are fully operational within two weeks.
Two weeks for most pharma clients. Onboarding covers configuring topics by product and therapeutic area, setting escalation protocols by team and geography, calibrating briefing formats for each stakeholder group, and running a parallel coverage audit against your current vendor so you see exactly what you have been missing.
Book a Demo
Find out what your current platform is missing in 20 minutes.
We will scope the call around your therapeutic areas and run a coverage audit against your current setup. No obligation.
No platform tour.